nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—SLC22A3—Vincristine—kidney cancer	0.345	1	CbGbCtD
Melphalan—Chlorambucil—GSTP1—kidney cancer	0.0106	0.872	CrCbGaD
Melphalan—SLC7A5—Basigin interactions—L1CAM—kidney cancer	0.00974	0.172	CbGpPWpGaD
Melphalan—SLC7A5—Sirolimus—Temsirolimus—kidney cancer	0.00604	0.5	CbGdCrCtD
Melphalan—SLC7A5—Sirolimus—Everolimus—kidney cancer	0.00604	0.5	CbGdCrCtD
Melphalan—SLC22A3—Abacavir transmembrane transport—ABCB1—kidney cancer	0.00548	0.0966	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUND—kidney cancer	0.00337	0.0593	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—L1CAM—kidney cancer	0.00324	0.0571	CbGpPWpGaD
Melphalan—SLC22A3—Abacavir transport and metabolism—ABCB1—kidney cancer	0.00315	0.0555	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.00229	0.0404	CbGpPWpGaD
Melphalan—SLC7A5—Amino acid and oligopeptide SLC transporters—SLC5A5—kidney cancer	0.00227	0.04	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—GRB7—kidney cancer	0.00177	0.0313	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.00168	0.0296	CbGpPWpGaD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.00134	0.0236	CbGpPWpGaD
Melphalan—SLC7A5—nephron tubule—kidney cancer	0.00132	0.196	CbGeAlD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.00127	0.0224	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.00113	0.02	CbGpPWpGaD
Melphalan—SLC7A5—cortex of kidney—kidney cancer	0.00113	0.168	CbGeAlD
Melphalan—SLC7A5—gonad—kidney cancer	0.00107	0.16	CbGeAlD
Melphalan—SLC7A5—cardiac atrium—kidney cancer	0.00107	0.16	CbGeAlD
Melphalan—SLC7A5—Transmembrane transport of small molecules—RYR1—kidney cancer	0.001	0.0177	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	0.000945	0.0166	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	0.000924	0.0163	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	0.000899	0.0158	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—L1CAM—kidney cancer	0.000878	0.0155	CbGpPWpGaD
Melphalan—Ibuprofen—PTGS1—kidney cancer	0.000757	0.062	CrCbGaD
Melphalan—SLC22A3—renal system—kidney cancer	0.000743	0.111	CbGeAlD
Melphalan—SLC22A3—kidney—kidney cancer	0.000719	0.107	CbGeAlD
Melphalan—SLC22A3—gonad—kidney cancer	0.000667	0.0992	CbGeAlD
Melphalan—SLC7A5—Hemostasis—ANXA2—kidney cancer	0.000665	0.0117	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000598	0.0105	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000577	0.0102	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000577	0.0102	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000576	0.0102	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000576	0.0102	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000576	0.0102	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—KCNMA1—kidney cancer	0.000551	0.00972	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000511	0.009	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GRB7—kidney cancer	0.000481	0.00848	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITPR2—kidney cancer	0.000447	0.00788	CbGpPWpGaD
Melphalan—Ibuprofen—PTGS2—kidney cancer	0.000433	0.0354	CrCbGaD
Melphalan—Pancytopenia—Capecitabine—kidney cancer	0.000419	0.000738	CcSEcCtD
Melphalan—Dyspepsia—Sorafenib—kidney cancer	0.000416	0.000733	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000414	0.00073	CcSEcCtD
Melphalan—Anaemia—Gemcitabine—kidney cancer	0.000413	0.000728	CcSEcCtD
Melphalan—Neutropenia—Capecitabine—kidney cancer	0.000412	0.000726	CcSEcCtD
Melphalan—Decreased appetite—Sorafenib—kidney cancer	0.000411	0.000724	CcSEcCtD
Melphalan—Anorexia—Dactinomycin—kidney cancer	0.00041	0.000723	CcSEcCtD
Melphalan—Nausea—Pazopanib—kidney cancer	0.00041	0.000722	CcSEcCtD
Melphalan—Neoplasm—Doxorubicin—kidney cancer	0.00041	0.000722	CcSEcCtD
Melphalan—Bladder pain—Doxorubicin—kidney cancer	0.00041	0.000722	CcSEcCtD
Melphalan—Mouth ulceration—Doxorubicin—kidney cancer	0.00041	0.000722	CcSEcCtD
Melphalan—Paraesthesia—Sunitinib—kidney cancer	0.000408	0.00072	CcSEcCtD
Melphalan—Convulsion—Vincristine—kidney cancer	0.000408	0.00072	CcSEcCtD
Melphalan—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000408	0.000719	CcSEcCtD
Melphalan—Fatigue—Sorafenib—kidney cancer	0.000407	0.000718	CcSEcCtD
Melphalan—Dyspnoea—Sunitinib—kidney cancer	0.000405	0.000714	CcSEcCtD
Melphalan—Pain—Sorafenib—kidney cancer	0.000404	0.000712	CcSEcCtD
Melphalan—Hypersensitivity—Vinblastine—kidney cancer	0.000403	0.00071	CcSEcCtD
Melphalan—Myalgia—Vincristine—kidney cancer	0.000401	0.000707	CcSEcCtD
Melphalan—Hypersensitivity—Everolimus—kidney cancer	0.000401	0.000707	CcSEcCtD
Melphalan—Dyspepsia—Sunitinib—kidney cancer	0.0004	0.000705	CcSEcCtD
Melphalan—Leukopenia—Gemcitabine—kidney cancer	0.0004	0.000705	CcSEcCtD
Melphalan—Flushing—Paclitaxel—kidney cancer	0.000399	0.000703	CcSEcCtD
Melphalan—Decreased appetite—Sunitinib—kidney cancer	0.000395	0.000697	CcSEcCtD
Melphalan—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000393	0.000692	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000392	0.000691	CcSEcCtD
Melphalan—Asthenia—Vinblastine—kidney cancer	0.000392	0.000691	CcSEcCtD
Melphalan—Fatigue—Sunitinib—kidney cancer	0.000392	0.000691	CcSEcCtD
Melphalan—Asthenia—Everolimus—kidney cancer	0.000391	0.000688	CcSEcCtD
Melphalan—Cough—Gemcitabine—kidney cancer	0.00039	0.000688	CcSEcCtD
Melphalan—Pain—Sunitinib—kidney cancer	0.000389	0.000685	CcSEcCtD
Melphalan—Immune system disorder—Paclitaxel—kidney cancer	0.000388	0.000684	CcSEcCtD
Melphalan—Mediastinal disorder—Paclitaxel—kidney cancer	0.000388	0.000683	CcSEcCtD
Melphalan—Neuropathy peripheral—Capecitabine—kidney cancer	0.000385	0.000679	CcSEcCtD
Melphalan—Pruritus—Everolimus—kidney cancer	0.000385	0.000679	CcSEcCtD
Melphalan—Anaphylactic shock—Vincristine—kidney cancer	0.000385	0.000678	CcSEcCtD
Melphalan—Oedema—Vincristine—kidney cancer	0.000385	0.000678	CcSEcCtD
Melphalan—Arrhythmia—Paclitaxel—kidney cancer	0.000384	0.000677	CcSEcCtD
Melphalan—Stomatitis—Capecitabine—kidney cancer	0.000383	0.000675	CcSEcCtD
Melphalan—Jaundice—Capecitabine—kidney cancer	0.000383	0.000675	CcSEcCtD
Melphalan—Infection—Vincristine—kidney cancer	0.000382	0.000673	CcSEcCtD
Melphalan—Myalgia—Gemcitabine—kidney cancer	0.000381	0.000671	CcSEcCtD
Melphalan—Chest pain—Gemcitabine—kidney cancer	0.000381	0.000671	CcSEcCtD
Melphalan—Alopecia—Paclitaxel—kidney cancer	0.00038	0.00067	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000378	0.000666	CcSEcCtD
Melphalan—Asthenia—Erlotinib—kidney cancer	0.000377	0.000664	CcSEcCtD
Melphalan—Thrombocytopenia—Vincristine—kidney cancer	0.000377	0.000664	CcSEcCtD
Melphalan—Urticaria—Sorafenib—kidney cancer	0.000375	0.000662	CcSEcCtD
Melphalan—Decreased appetite—Dactinomycin—kidney cancer	0.000374	0.000659	CcSEcCtD
Melphalan—Diarrhoea—Vinblastine—kidney cancer	0.000374	0.000659	CcSEcCtD
Melphalan—Diarrhoea—Everolimus—kidney cancer	0.000373	0.000656	CcSEcCtD
Melphalan—Hepatobiliary disease—Capecitabine—kidney cancer	0.000372	0.000655	CcSEcCtD
Melphalan—Pruritus—Erlotinib—kidney cancer	0.000372	0.000655	CcSEcCtD
Melphalan—Fatigue—Dactinomycin—kidney cancer	0.000371	0.000654	CcSEcCtD
Melphalan—Pain—Dactinomycin—kidney cancer	0.000368	0.000649	CcSEcCtD
Melphalan—Ibuprofen—ABCB1—kidney cancer	0.000368	0.0301	CrCbGaD
Melphalan—Anorexia—Vincristine—kidney cancer	0.000367	0.000646	CcSEcCtD
Melphalan—Anaphylactic shock—Gemcitabine—kidney cancer	0.000365	0.000643	CcSEcCtD
Melphalan—Oedema—Gemcitabine—kidney cancer	0.000365	0.000643	CcSEcCtD
Melphalan—Infection—Gemcitabine—kidney cancer	0.000363	0.000639	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—KRAS—kidney cancer	0.000362	0.00637	CbGpPWpGaD
Melphalan—Diarrhoea—Erlotinib—kidney cancer	0.000359	0.000633	CcSEcCtD
Melphalan—Hypotension—Vincristine—kidney cancer	0.000359	0.000633	CcSEcCtD
Melphalan—Thrombocytopenia—Gemcitabine—kidney cancer	0.000357	0.00063	CcSEcCtD
Melphalan—Renal failure acute—Doxorubicin—kidney cancer	0.000356	0.000628	CcSEcCtD
Melphalan—Haemoglobin—Capecitabine—kidney cancer	0.000355	0.000625	CcSEcCtD
Melphalan—Skin disorder—Gemcitabine—kidney cancer	0.000354	0.000625	CcSEcCtD
Melphalan—Haemorrhage—Capecitabine—kidney cancer	0.000353	0.000622	CcSEcCtD
Melphalan—Hepatitis—Capecitabine—kidney cancer	0.000353	0.000622	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00035	0.000618	CcSEcCtD
Melphalan—Urinary tract disorder—Capecitabine—kidney cancer	0.000349	0.000614	CcSEcCtD
Melphalan—Hypersensitivity—Sorafenib—kidney cancer	0.000348	0.000614	CcSEcCtD
Melphalan—Anorexia—Gemcitabine—kidney cancer	0.000348	0.000613	CcSEcCtD
Melphalan—Vomiting—Vinblastine—kidney cancer	0.000348	0.000612	CcSEcCtD
Melphalan—Connective tissue disorder—Capecitabine—kidney cancer	0.000347	0.000611	CcSEcCtD
Melphalan—Vomiting—Everolimus—kidney cancer	0.000346	0.00061	CcSEcCtD
Melphalan—Anaemia—Paclitaxel—kidney cancer	0.000346	0.00061	CcSEcCtD
Melphalan—Urethral disorder—Capecitabine—kidney cancer	0.000346	0.00061	CcSEcCtD
Melphalan—Paraesthesia—Vincristine—kidney cancer	0.000345	0.000609	CcSEcCtD
Melphalan—Rash—Everolimus—kidney cancer	0.000343	0.000605	CcSEcCtD
Melphalan—Dermatitis—Everolimus—kidney cancer	0.000343	0.000604	CcSEcCtD
Melphalan—Hypotension—Gemcitabine—kidney cancer	0.000341	0.000601	CcSEcCtD
Melphalan—Asthenia—Sorafenib—kidney cancer	0.000339	0.000598	CcSEcCtD
Melphalan—Leukopenia—Paclitaxel—kidney cancer	0.000335	0.00059	CcSEcCtD
Melphalan—Hypersensitivity—Sunitinib—kidney cancer	0.000335	0.00059	CcSEcCtD
Melphalan—Decreased appetite—Vincristine—kidney cancer	0.000334	0.000589	CcSEcCtD
Melphalan—Pruritus—Sorafenib—kidney cancer	0.000334	0.000589	CcSEcCtD
Melphalan—Vomiting—Erlotinib—kidney cancer	0.000334	0.000589	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000332	0.000586	CcSEcCtD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—kidney cancer	0.000332	0.00586	CbGpPWpGaD
Melphalan—Gastrointestinal disorder—Vincristine—kidney cancer	0.000332	0.000585	CcSEcCtD
Melphalan—Fatigue—Vincristine—kidney cancer	0.000332	0.000584	CcSEcCtD
Melphalan—Rash—Erlotinib—kidney cancer	0.000331	0.000584	CcSEcCtD
Melphalan—Dermatitis—Erlotinib—kidney cancer	0.000331	0.000583	CcSEcCtD
Melphalan—Hyponatraemia—Doxorubicin—kidney cancer	0.00033	0.000582	CcSEcCtD
Melphalan—Pain—Vincristine—kidney cancer	0.000329	0.00058	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—IFNA1—kidney cancer	0.000328	0.00579	CbGpPWpGaD
Melphalan—Paraesthesia—Gemcitabine—kidney cancer	0.000328	0.000577	CcSEcCtD
Melphalan—Flushing—Capecitabine—kidney cancer	0.000328	0.000577	CcSEcCtD
Melphalan—Cough—Paclitaxel—kidney cancer	0.000327	0.000576	CcSEcCtD
Melphalan—Asthenia—Sunitinib—kidney cancer	0.000326	0.000575	CcSEcCtD
Melphalan—Dyspnoea—Gemcitabine—kidney cancer	0.000325	0.000573	CcSEcCtD
Melphalan—Nausea—Vinblastine—kidney cancer	0.000325	0.000572	CcSEcCtD
Melphalan—Convulsion—Paclitaxel—kidney cancer	0.000324	0.000572	CcSEcCtD
Melphalan—Nausea—Everolimus—kidney cancer	0.000323	0.00057	CcSEcCtD
Melphalan—Diarrhoea—Sorafenib—kidney cancer	0.000323	0.00057	CcSEcCtD
Melphalan—Pruritus—Sunitinib—kidney cancer	0.000322	0.000567	CcSEcCtD
Melphalan—Immune system disorder—Capecitabine—kidney cancer	0.000319	0.000562	CcSEcCtD
Melphalan—Chest pain—Paclitaxel—kidney cancer	0.000319	0.000562	CcSEcCtD
Melphalan—Myalgia—Paclitaxel—kidney cancer	0.000319	0.000562	CcSEcCtD
Melphalan—Mediastinal disorder—Capecitabine—kidney cancer	0.000318	0.00056	CcSEcCtD
Melphalan—Decreased appetite—Gemcitabine—kidney cancer	0.000317	0.000559	CcSEcCtD
Melphalan—Hypersensitivity—Dactinomycin—kidney cancer	0.000317	0.000559	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000317	0.000558	CcSEcCtD
Melphalan—Arrhythmia—Capecitabine—kidney cancer	0.000315	0.000556	CcSEcCtD
Melphalan—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000315	0.000555	CcSEcCtD
Melphalan—Fatigue—Gemcitabine—kidney cancer	0.000315	0.000554	CcSEcCtD
Melphalan—Cardiac arrest—Doxorubicin—kidney cancer	0.000313	0.000551	CcSEcCtD
Melphalan—Pain—Gemcitabine—kidney cancer	0.000312	0.00055	CcSEcCtD
Melphalan—Nausea—Erlotinib—kidney cancer	0.000312	0.00055	CcSEcCtD
Melphalan—Alopecia—Capecitabine—kidney cancer	0.000312	0.00055	CcSEcCtD
Melphalan—Diarrhoea—Sunitinib—kidney cancer	0.000311	0.000548	CcSEcCtD
Melphalan—Asthenia—Dactinomycin—kidney cancer	0.000309	0.000544	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—IFNA2—kidney cancer	0.000306	0.00538	CbGpPWpGaD
Melphalan—Oedema—Paclitaxel—kidney cancer	0.000306	0.000538	CcSEcCtD
Melphalan—Anaphylactic shock—Paclitaxel—kidney cancer	0.000306	0.000538	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000305	0.00537	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000304	0.00535	CbGpPWpGaD
Melphalan—Liver function test abnormal—Doxorubicin—kidney cancer	0.000304	0.000535	CcSEcCtD
Melphalan—Infection—Paclitaxel—kidney cancer	0.000304	0.000535	CcSEcCtD
Melphalan—Vomiting—Sorafenib—kidney cancer	0.0003	0.00053	CcSEcCtD
Melphalan—Thrombocytopenia—Paclitaxel—kidney cancer	0.000299	0.000527	CcSEcCtD
Melphalan—Tachycardia—Paclitaxel—kidney cancer	0.000298	0.000525	CcSEcCtD
Melphalan—Rash—Sorafenib—kidney cancer	0.000298	0.000525	CcSEcCtD
Melphalan—Dermatitis—Sorafenib—kidney cancer	0.000298	0.000525	CcSEcCtD
Melphalan—Skin disorder—Paclitaxel—kidney cancer	0.000297	0.000523	CcSEcCtD
Melphalan—Diarrhoea—Dactinomycin—kidney cancer	0.000295	0.000519	CcSEcCtD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000294	0.00518	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000293	0.00517	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000293	0.00517	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000293	0.00517	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000293	0.00517	CbGpPWpGaD
Melphalan—Anorexia—Paclitaxel—kidney cancer	0.000291	0.000513	CcSEcCtD
Melphalan—Vomiting—Sunitinib—kidney cancer	0.000289	0.00051	CcSEcCtD
Melphalan—Rash—Sunitinib—kidney cancer	0.000287	0.000505	CcSEcCtD
Melphalan—Dermatitis—Sunitinib—kidney cancer	0.000286	0.000505	CcSEcCtD
Melphalan—Hypotension—Paclitaxel—kidney cancer	0.000285	0.000503	CcSEcCtD
Melphalan—Anaemia—Capecitabine—kidney cancer	0.000284	0.0005	CcSEcCtD
Melphalan—Hypersensitivity—Vincristine—kidney cancer	0.000283	0.000499	CcSEcCtD
Melphalan—Nausea—Sorafenib—kidney cancer	0.000281	0.000495	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000278	0.00049	CcSEcCtD
Melphalan—Asthenia—Vincristine—kidney cancer	0.000276	0.000486	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—IGF2—kidney cancer	0.000275	0.00485	CbGpPWpGaD
Melphalan—Leukopenia—Capecitabine—kidney cancer	0.000275	0.000485	CcSEcCtD
Melphalan—Paraesthesia—Paclitaxel—kidney cancer	0.000274	0.000483	CcSEcCtD
Melphalan—Vomiting—Dactinomycin—kidney cancer	0.000274	0.000482	CcSEcCtD
Melphalan—Dyspnoea—Paclitaxel—kidney cancer	0.000272	0.00048	CcSEcCtD
Melphalan—Rash—Dactinomycin—kidney cancer	0.000271	0.000478	CcSEcCtD
Melphalan—Nausea—Sunitinib—kidney cancer	0.00027	0.000476	CcSEcCtD
Melphalan—Pancytopenia—Doxorubicin—kidney cancer	0.00027	0.000476	CcSEcCtD
Melphalan—Dyspepsia—Paclitaxel—kidney cancer	0.000269	0.000474	CcSEcCtD
Melphalan—Cough—Capecitabine—kidney cancer	0.000268	0.000472	CcSEcCtD
Melphalan—Neutropenia—Doxorubicin—kidney cancer	0.000266	0.000468	CcSEcCtD
Melphalan—Decreased appetite—Paclitaxel—kidney cancer	0.000266	0.000468	CcSEcCtD
Melphalan—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000264	0.000465	CcSEcCtD
Melphalan—Fatigue—Paclitaxel—kidney cancer	0.000263	0.000464	CcSEcCtD
Melphalan—Diarrhoea—Vincristine—kidney cancer	0.000263	0.000464	CcSEcCtD
Melphalan—Asthenia—Gemcitabine—kidney cancer	0.000262	0.000461	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ACY1—kidney cancer	0.000262	0.00461	CbGpPWpGaD
Melphalan—Chest pain—Capecitabine—kidney cancer	0.000262	0.000461	CcSEcCtD
Melphalan—Myalgia—Capecitabine—kidney cancer	0.000262	0.000461	CcSEcCtD
Melphalan—Pain—Paclitaxel—kidney cancer	0.000261	0.00046	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00026	0.000458	CcSEcCtD
Melphalan—Pruritus—Gemcitabine—kidney cancer	0.000258	0.000455	CcSEcCtD
Melphalan—Nausea—Dactinomycin—kidney cancer	0.000256	0.000451	CcSEcCtD
Melphalan—Oedema—Capecitabine—kidney cancer	0.000251	0.000442	CcSEcCtD
Melphalan—Diarrhoea—Gemcitabine—kidney cancer	0.00025	0.00044	CcSEcCtD
Melphalan—Infection—Capecitabine—kidney cancer	0.000249	0.000439	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000248	0.000438	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—kidney cancer	0.000247	0.000435	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—kidney cancer	0.000247	0.000435	CcSEcCtD
Melphalan—Thrombocytopenia—Capecitabine—kidney cancer	0.000245	0.000433	CcSEcCtD
Melphalan—Tachycardia—Capecitabine—kidney cancer	0.000245	0.000431	CcSEcCtD
Melphalan—Vomiting—Vincristine—kidney cancer	0.000245	0.000431	CcSEcCtD
Melphalan—Skin disorder—Capecitabine—kidney cancer	0.000244	0.000429	CcSEcCtD
Melphalan—Urticaria—Paclitaxel—kidney cancer	0.000243	0.000428	CcSEcCtD
Melphalan—Rash—Vincristine—kidney cancer	0.000243	0.000427	CcSEcCtD
Melphalan—Dermatitis—Vincristine—kidney cancer	0.000242	0.000427	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—kidney cancer	0.00024	0.000422	CcSEcCtD
Melphalan—Anorexia—Capecitabine—kidney cancer	0.000239	0.000421	CcSEcCtD
Melphalan—Hypotension—Capecitabine—kidney cancer	0.000234	0.000413	CcSEcCtD
Melphalan—Vomiting—Gemcitabine—kidney cancer	0.000232	0.000409	CcSEcCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000232	0.00408	CbGpPWpGaD
Melphalan—Rash—Gemcitabine—kidney cancer	0.00023	0.000405	CcSEcCtD
Melphalan—Dermatitis—Gemcitabine—kidney cancer	0.00023	0.000405	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—kidney cancer	0.000229	0.000403	CcSEcCtD
Melphalan—Nausea—Vincristine—kidney cancer	0.000228	0.000403	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000228	0.000403	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—kidney cancer	0.000227	0.000401	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—kidney cancer	0.000227	0.000401	CcSEcCtD
Melphalan—Paraesthesia—Capecitabine—kidney cancer	0.000225	0.000397	CcSEcCtD
Melphalan—Hypersensitivity—Paclitaxel—kidney cancer	0.000225	0.000397	CcSEcCtD
Melphalan—Urinary tract disorder—Doxorubicin—kidney cancer	0.000225	0.000396	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—kidney cancer	0.000224	0.000394	CcSEcCtD
Melphalan—Dyspnoea—Capecitabine—kidney cancer	0.000224	0.000394	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—kidney cancer	0.000223	0.000393	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PDHB—kidney cancer	0.000222	0.00392	CbGpPWpGaD
Melphalan—Dyspepsia—Capecitabine—kidney cancer	0.000221	0.000389	CcSEcCtD
Melphalan—Asthenia—Paclitaxel—kidney cancer	0.000219	0.000386	CcSEcCtD
Melphalan—Decreased appetite—Capecitabine—kidney cancer	0.000218	0.000384	CcSEcCtD
Melphalan—Nausea—Gemcitabine—kidney cancer	0.000217	0.000382	CcSEcCtD
Melphalan—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000216	0.000381	CcSEcCtD
Melphalan—Fatigue—Capecitabine—kidney cancer	0.000216	0.000381	CcSEcCtD
Melphalan—Pruritus—Paclitaxel—kidney cancer	0.000216	0.000381	CcSEcCtD
Melphalan—Pain—Capecitabine—kidney cancer	0.000214	0.000378	CcSEcCtD
Melphalan—Flushing—Doxorubicin—kidney cancer	0.000211	0.000372	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CCBL1—kidney cancer	0.000209	0.00369	CbGpPWpGaD
Melphalan—Diarrhoea—Paclitaxel—kidney cancer	0.000209	0.000368	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—kidney cancer	0.000205	0.000362	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—kidney cancer	0.000205	0.000361	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—kidney cancer	0.000203	0.000358	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—kidney cancer	0.000201	0.000354	CcSEcCtD
Melphalan—Urticaria—Capecitabine—kidney cancer	0.000199	0.000351	CcSEcCtD
Melphalan—Vomiting—Paclitaxel—kidney cancer	0.000194	0.000342	CcSEcCtD
Melphalan—Rash—Paclitaxel—kidney cancer	0.000193	0.000339	CcSEcCtD
Melphalan—Dermatitis—Paclitaxel—kidney cancer	0.000192	0.000339	CcSEcCtD
Melphalan—Hypersensitivity—Capecitabine—kidney cancer	0.000185	0.000325	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—kidney cancer	0.000183	0.000323	CcSEcCtD
Melphalan—Nausea—Paclitaxel—kidney cancer	0.000181	0.00032	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PPAT—kidney cancer	0.000181	0.0032	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GLIPR1—kidney cancer	0.000181	0.0032	CbGpPWpGaD
Melphalan—Asthenia—Capecitabine—kidney cancer	0.00018	0.000317	CcSEcCtD
Melphalan—Pruritus—Capecitabine—kidney cancer	0.000177	0.000313	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—kidney cancer	0.000177	0.000312	CcSEcCtD
Melphalan—Cough—Doxorubicin—kidney cancer	0.000173	0.000304	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—kidney cancer	0.000172	0.000302	CcSEcCtD
Melphalan—Diarrhoea—Capecitabine—kidney cancer	0.000172	0.000302	CcSEcCtD
Melphalan—SLC22A3—Metabolism—APRT—kidney cancer	0.000169	0.00297	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—FH—kidney cancer	0.000169	0.00297	CbGpPWpGaD
Melphalan—Myalgia—Doxorubicin—kidney cancer	0.000169	0.000297	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—kidney cancer	0.000169	0.000297	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000167	0.000295	CcSEcCtD
Melphalan—Oedema—Doxorubicin—kidney cancer	0.000162	0.000285	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—kidney cancer	0.000162	0.000285	CcSEcCtD
Melphalan—Infection—Doxorubicin—kidney cancer	0.000161	0.000283	CcSEcCtD
Melphalan—Vomiting—Capecitabine—kidney cancer	0.000159	0.000281	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GPC3—kidney cancer	0.000159	0.00279	CbGpPWpGaD
Melphalan—Thrombocytopenia—Doxorubicin—kidney cancer	0.000158	0.000279	CcSEcCtD
Melphalan—Rash—Capecitabine—kidney cancer	0.000158	0.000279	CcSEcCtD
Melphalan—Dermatitis—Capecitabine—kidney cancer	0.000158	0.000278	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—kidney cancer	0.000158	0.000278	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—kidney cancer	0.000157	0.000277	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000155	0.00273	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CA2—kidney cancer	0.000154	0.00272	CbGpPWpGaD
Melphalan—Anorexia—Doxorubicin—kidney cancer	0.000154	0.000271	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—RAF1—kidney cancer	0.000151	0.00267	CbGpPWpGaD
Melphalan—Hypotension—Doxorubicin—kidney cancer	0.000151	0.000266	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ALAD—kidney cancer	0.00015	0.00265	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000149	0.00263	CbGpPWpGaD
Melphalan—Nausea—Capecitabine—kidney cancer	0.000149	0.000262	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000147	0.000259	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ST3GAL2—kidney cancer	0.000147	0.00258	CbGpPWpGaD
Melphalan—Paraesthesia—Doxorubicin—kidney cancer	0.000145	0.000256	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—kidney cancer	0.000144	0.000254	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ALDH1A1—kidney cancer	0.000143	0.00253	CbGpPWpGaD
Melphalan—Dyspepsia—Doxorubicin—kidney cancer	0.000142	0.000251	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—kidney cancer	0.00014	0.000248	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.00014	0.000246	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—kidney cancer	0.000139	0.000246	CcSEcCtD
Melphalan—Pain—Doxorubicin—kidney cancer	0.000138	0.000244	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PGK1—kidney cancer	0.000137	0.00242	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC5A3—kidney cancer	0.000137	0.00242	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL2—kidney cancer	0.000136	0.00239	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—LDHB—kidney cancer	0.000135	0.00238	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000131	0.00231	CbGpPWpGaD
Melphalan—Urticaria—Doxorubicin—kidney cancer	0.000128	0.000226	CcSEcCtD
Melphalan—Hypersensitivity—Doxorubicin—kidney cancer	0.000119	0.00021	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000118	0.00208	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CA9—kidney cancer	0.000117	0.00206	CbGpPWpGaD
Melphalan—Asthenia—Doxorubicin—kidney cancer	0.000116	0.000204	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—VEGFA—kidney cancer	0.000115	0.00203	CbGpPWpGaD
Melphalan—Pruritus—Doxorubicin—kidney cancer	0.000114	0.000201	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—kidney cancer	0.000111	0.000195	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—MAPK3—kidney cancer	0.000109	0.00192	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK1—kidney cancer	0.000104	0.00183	CbGpPWpGaD
Melphalan—Vomiting—Doxorubicin—kidney cancer	0.000103	0.000181	CcSEcCtD
Melphalan—Rash—Doxorubicin—kidney cancer	0.000102	0.00018	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—kidney cancer	0.000102	0.000179	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CRABP1—kidney cancer	9.94e-05	0.00175	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—KRAS—kidney cancer	9.81e-05	0.00173	CbGpPWpGaD
Melphalan—Nausea—Doxorubicin—kidney cancer	9.6e-05	0.000169	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ITPR2—kidney cancer	9.24e-05	0.00163	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—kidney cancer	9.01e-05	0.00159	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TP53—kidney cancer	8.72e-05	0.00154	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTT1—kidney cancer	8.42e-05	0.00148	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ACHE—kidney cancer	8.42e-05	0.00148	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SCARB1—kidney cancer	7.97e-05	0.00141	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTGS1—kidney cancer	7.89e-05	0.00139	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PSMD7—kidney cancer	7.74e-05	0.00136	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—BCHE—kidney cancer	7.34e-05	0.00129	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC5A5—kidney cancer	7.25e-05	0.00128	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC2A1—kidney cancer	7e-05	0.00123	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—RAF1—kidney cancer	6.68e-05	0.00118	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTP1—kidney cancer	5.84e-05	0.00103	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCB1—kidney cancer	5.53e-05	0.000974	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTM1—kidney cancer	5.37e-05	0.000946	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CYP1A1—kidney cancer	5.09e-05	0.000896	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—POMC—kidney cancer	3.79e-05	0.000668	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTGS2—kidney cancer	3.02e-05	0.000533	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PTEN—kidney cancer	2.64e-05	0.000465	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—kidney cancer	1.86e-05	0.000328	CbGpPWpGaD
